Researchers identify protein pathway involved in Parkinson disease developmentJune 19, 2007Scientists have found a novel signaling pathway in cells that is altered by genetic mutations recently identified in Parkinson disease development. These new findings show how the mutations affect cellular function and could provide a target for drug therapies to treat the disease. The research by a team of Emory University scientists will be published June 18 in the Public Library of Science Biology (PLoS Biology) journal. Parkinson disease is a degenerative disorder of the central nervous system resulting from the loss of neurons in the brain that produce dopamine. This lowering of dopamine leads to decreased stimulation of the brain's motor cortex. Although scientists have not known the exact cause of the loss of these dopamine-producing neurons, they believe it is related to dysfunctional mitochondria and oxidative stress. Mitochondria are the cell's "power plants," which metabolize oxygen and generate energy. Oxidative stress is the damage caused to cells by reactive oxygen produced during oxygen metabolism. Although cells have mechanisms in place to protect against oxidative damage, this system can break down in the face of environmental challenges or genetic mutations.
The Emory researchers found that the mitochondrial protein PINK1 normally protects cells from oxidative stress and promotes cell survival by regulating function of the protein TRAP1. When PINK1 is mutated, however, the protective TRAP1 pathway is disrupted, leading to mitochondrial damage. Other scientists recently have linked early onset Parkinson disease to mutations in both copies of the PINK1 gene (one from each parent). They also have evidence that single-copy mutations in PINK1 are a significant risk factor for the development of later-onset Parkinson disease. "We now know much more about the effect of PINK1 mutations on the mitochondria and how this novel signaling pathway is disrupted in the development of Parkinson disease," says Lian Li, PhD, associate professor of pharmacology in Emory University School of Medicine and research team leader. "We believe the PINK1 and TRAP1 pathway may be a future target for therapeutic intervention." Emory University | |||||||||||||||||||||
|
Related Parkinson Disease Current Events and Parkinson Disease News Articles Lessons from yeast: A possible cure for Parkinson's disease? Parkinson disease (PD) is a debilitating and lethal neurodegenerative disease, for which there is currently no cure. It is caused by the progressive loss of nerve cells that produce the chemical dopamine and is characterized by the accumulation of abnormal aggregates of a protein called alpha-syn in these dopaminergic nerve cells. New Study Shows that Fetal Cells Transplanted into the Brain to Treat Parkinson's Disease May Not Function Long Term Neurons grafted into the brain of a patient with Parkinson's disease fourteen years ago have developed Lewy body pathology, the defining pathology for the disease, according to research by Jeffrey H. Kordower, PhD, and associates and published in the April 6 issue of Nature Medicine. Family study bolsters link between pesticides and Parkinson's For the first time, the association between Parkinson's disease and exposure to pesticides has been shown in patients with the neurological disorder compared with their unaffected relatives, according to a study in the online open access journal BMC Neurology. Practice parameters discuss treatment for narcolepsy, other hypersomnias of central origin Practice parameters published in the December 1 issue of the journal SLEEP serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin, including idiopathic hypersomnia, recurrent hypersomnia and hypersomnia due to medical condition. PINK1 protects from Parkinson's Parkinson disease (PD) is a common neurodegenerative disease characterized by the selective loss of midbrain dopaminergic neurons. Medical therapy for restless legs syndrome may trigger compulsive gambling Compulsive gambling with extreme losses — in two cases, greater than $100,000 — by people without a prior history of gambling problems has been linked to a class of drugs commonly used to treat the neurological disorder restless legs syndrome (RLS). Drug improves tremors, involuntary movements in Parkinson patients A drug used to treat epilepsy has been found to significantly improve tremors, motor fluctuations, and other involuntary movements, or dyskinesias, in patients with Parkinson disease. Parkinson disease can lead to errors on driving test People with Parkinson disease were more likely to make more safety mistakes during a driving test than people with no neurological disorders, according to a study published in the November 28, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology. Multi-tasking adversely affects brain's learning, UCLA psychologists report Multi-tasking affects the brain's learning systems, and as a result, we do not learn as well when we are distracted, UCLA psychologists report this week in the online edition of Proceedings of the National Academy of Sciences. Parkinson patients can be apathetic without depression People with Parkinson disease can be apathetic without being depressed, and apathy may be a core feature of the disease. More Parkinson Disease Current Events and Parkinson Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||